Smoking makes psoriatic arthritis drugs less effective

| Melissa Leavitt

Smoking may make some treatments for psoriatic arthritis less effective, according to the results of a recent study.

In an analysis of treatment outcomes for patients taking certain kinds of biologics, a team of Danish researchers found that smokers do not improve as much, and do not stick with the treatment for as long, as nonsmokers.

The study, published last month in Annals of the Rheumatic Diseases, examined the impact of smoking on treatment with the tumor necrosis factor-alpha (TNF-alpha) inhibitor drugs Enbrel (etanercept), Remicade (infliximab) and Humira (adalimumab). A cytokine, or protein, involved in inflammation, TNF-alpha is a common target for psoriatic disease treatments. 

Using a Danish patient database called the DANBIO registry, researchers studied 1,148 people taking TNF-alpha inhibitors for psoriatic arthritis. Among this group, 33 percent were current smokers and 41 percent had never smoked. The remaining 26 percent were classified as previous smokers, who stopped smoking by the time they started treatment.

Before starting treatment, smokers were in poorer health than never-smokers or previous smokers, according to the study. They also had been diagnosed with psoriatic arthritis more recently, the researchers report, which could indicate that their symptoms were more aggressive.

After six months of treatment, only 24 percent of smokers improved by 20 percent (a measurement known as ACR20), compared with 33 percent of never-smokers, according to the study results. Using a different measure of improvement, researchers found that only 23 percent of smokers achieved EULAR-good-response after 6 months, compared with 34 percent of never-smokers. EULAR-good-response is determined by the number of swollen and tender joints a patient has. 

Researchers also found that smokers stayed on TNF-alpha inhibitors for less time than nonsmokers. The median treatment duration was 1.56 years for smokers, compared with 2.43 years for never-smokers. 

Therapy with TNF-alpha inhibitors is generally considered to be an effective treatment for psoriatic arthritis, the researchers note. However, they explain, previous studies have shown that only approximately 60 percent of patients achieve ACR20 while on these drugs. This study indicates that smoking may be a lifestyle factor that can make TNF-alpha treatment less effective.


Driving discovery, creating community

For more than 50 years, we’ve been driving efforts to cure psoriatic disease and improve the lives of those affected. But there’s still plenty to do! Learn how you can help our advocacy team shape the laws and policies that affect people with psoriasis and psoriatic arthritis – in your state and across the country. Help us raise funds to support research by joining Team NPF, where you can walk, run, cycle, play bingo or create your own fundraising event. If you or someone you love needs free, personalized support for living a healthier life with psoriatic disease, contact our Patient Navigation Center. And keep the National Psoriasis Foundation going strong by making a donation today. Together, we will find a cure.

Recent Advance Posts

Easy on the joints and mentally soothing, aquatic exercises offer many benefits...
Innovations in drug therapy have changed the landscape since these individuals...
Andrew Blauvelt, M.D., MBA, sheds light on the importance of clinical trials...
With help from his old bike and a biologic, Barry Bonner overcomes PsA and...
Rheumatologists and dermatologists join forces to defeat a common enemy.
Psoriasis updates from the 76th annual meeting of the American Academy of...
Culinary enthusiasts offer grade-A tips for taking the aches and pains out of...
For some psoriasis patients, getting the right diagnosis isn’t always so black...
NPF launches a clearinghouse for clinical trial info, including how to find one...